Novavax, a clinical-stage vaccine company focused on the discovery, development and commercialisation of recombinant nanoparticle vaccines and adjuvants, has named Iksung Cho as Vice President, Biostatistics.
Cho joined the Rockville, MD, US-based firm in December 2015 as Executive Director, Biostatistics with responsibility for coordinating statistical and statistical programming activities for vaccine candidates in various stages of clinical development.
Prior to joining Novavax he was Senior Statistician at PATH, an international nonprofit organisation that aims to accelerate innovation across vaccines, drugs, diagnostics, devices and system and service innovations.
Cho has held positions of increasing responsibility in biostatistics and data management at Aviron, Merck and MedImmune, where he was Vice President of Global Biostatistics.
